Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human TNFRSF12A protein

Cat.No. : TNFRSF12A-582H
Product Overview : Recombinant Human TNFRSF12A protein was expressed in Escherichia coli.
  • Specification
  • Gene Information
  • Related Products
Description : Human TNF-related weak inducer of apoptosis receptor (TWEAKR) also known as Tumor necrosis factor receptor superfamily member 12A precursor (gene name TNFRSF12A) or fibroblast growth factor-inducable 14 kD protein, is distantly related to the TNFR family, containing one cysteine-rich domain in the extracellular region and a TNFR-associated factor binding domain but does not contain a death domain (DD) cytoplasmic region. It is expressed in the spleen, thymus, peripheral blood lymphocytes, colon, and small intestine. Signal transduction by TWEAK receptor can be activated by either the membrane anchored or the soluble TWEAK. In addition, It plays a role in TWEAK-induced endothelial cell migration, proliferation, and angiogenesis. Human and mouse TWEAK R share 82 % a.a. sequence identity.
Source : E.coli
Species : Human
Form : Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4.
Bio-activity : Fully biologically active when compared to standard. The ED50 as determined by inhibiting TWEAK-dependent proliferation of human umbilical vein endothelial cells (HUVEC) is less than 30 ng/ml, corresponding to a specific activity of > 3.3 × 10⁴ IU/mg, in the presence of 15 ng/ml of rHuTWEAK.
Molecular Mass : Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids.
Protein length : 53
AA Sequence : EQAPGTAPCSRGSSWSADLDKCMDC ASCRARPHSDFCLGCAAAPPAPFRL LWP
Endotoxin : Less than 1 EU/μg of rHuTWEAK Receptor as determined by LAL method.
Purity : >95% by SDS-PAGE and HPLC analysis.
Storage : Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 centigrade as supplied. 1 month, 2 to 8 centigrade under sterile conditions after reconstitution. 3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution : We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20 centigrade. Further dilutions should be made in appropriate buffered solutions.
Gene Name : TNFRSF12A
Official Symbol : TNFRSF12A
Synonyms : TNFRSF12A; tumor necrosis factor receptor superfamily, member 12A; tumor necrosis factor receptor superfamily member 12A; CD266; FN14; TweakR; tweak-receptor; FGF-inducible 14; type I transmembrane protein Fn14; fibroblast growth factor-inducible immediate-early response protein 14; TWEAKR;
Gene ID : 51330
mRNA Refseq : NM_016639
Protein Refseq : NP_057723
MIM : 605914
UniProt ID : Q9NP84

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
Can TNFRSF12A be a potential therapeutic target for cardiovascular diseases? 05/14/2022

Some studies suggest that TNFRSF12A may play a role in cardiovascular diseases, and targeting it could be a potential therapeutic strategy, but more research is needed.

Can TNFRSF12A be used as a diagnostic marker for certain diseases? 02/09/2021

Research indicates that elevated levels of TNFRSF12A may serve as a diagnostic marker for certain cancers, providing valuable information for disease detection.

Are there any FDA-approved drugs targeting TNFRSF12A? 05/10/2020

As of now, there are no FDA-approved drugs specifically targeting TNFRSF12A. However, research is ongoing to develop targeted therapies.

How is TNFRSF12A involved in inflammation? 01/31/2018

TNFRSF12A is known to modulate inflammatory responses, and dysregulation of its signaling pathways may contribute to chronic inflammatory conditions.

Can TNFRSF12A be targeted for immunotherapy in cancer treatment? 11/17/2017

TNFRSF12A is being explored as a potential target for immunotherapy in cancer, with studies investigating its role in modulating the immune response.

Customer Reviews (3)

Write a review
Reviews
11/26/2020

    The manufacturer's commitment to delivering excellent technical support further enhances the experience, offering timely resolutions to any challenges I may encounter.

    09/08/2019

      the TNFRSF12A protein surpasses expectations in terms of quality, meeting the rigorous demands of my experiments.

      06/16/2019

        With the TNFRSF12A protein and the manufacturer's support, I can confidently pursue my research goals and achieve meaningful outcomes.

        Ask a Question for All TNFRSF12A Products

        Required fields are marked with *

        My Review for All TNFRSF12A Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends